What is zegalogue?

What is Zegalogue used for?

Zegalogue is a prescription glucagon analog approved to treat severe hypoglycemia in people with diabetes. It works by raising blood glucose levels quickly when a patient cannot eat or drink safely.

How does Zegalogue work?

It mimics the action of natural glucagon, a hormone that signals the liver to release stored glucose into the blood. The drug comes ready-to-use in an auto-injector or prefilled syringe that people without medical training can give.

When does Zegalogue patent expire?

The primary U.S. patent on the dasiglucagon formulation expires in 2035. [1]

Why are companies challenging this patent?

No active patent challenges have been filed against dasiglucagon in the U.S. Patent and Trademark Office. The absence of early generic filings suggests developers view the remaining exclusivity period as viable.

Can biosimilars enter before patent expiry?

Zegalogue is a small synthetic peptide rather than a biologic, so biosimilar pathways do not apply. Generic versions will become available once patents expire.

What side effects are patients asking about?

Common complaints include nausea, vomiting, headache, and injection-site reactions. Severe reactions are rare.

Who makes Zegalogue?

Zealand Pharma produces the drug and handles marketing through its U.S. partner Beta Bionics for the auto-injector version.

How does Zegalogue compare with Gvoke?

Zegalogue uses dasiglucagon, a stable synthetic analog. Gvoke uses native glucagon in a stable liquid formulation. Both devices are ready-to-use, but some patients report different tolerability profiles.

Pricing and insurance coverage

List price sits at roughly $280 per dose. Most commercial insurance plans cover it after deductible, but Medicare Part D plans show variable coverage.

How does Zegalogue compare with Baqsimi?

Baqsimi is a nasal glucagon spray that requires no injection. Zegalogue remains an injectable option for patients who prefer familiar needle-based devices or who cannot use nasal sprays.

When does Zegalogue exclusivity expire?

Regulatory exclusivity runs through 2026 in the U.S., adding short-term protection beyond any basic compound patents.